Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Retrospective Study: Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Sponsor: Janssen Scientific Affairs, LLC
This observational or N/A phase trial investigates Cancer and Deep-vein Thrombosis of the Lower and Upper Extremities and is currently completed. Janssen Scientific Affairs, LLC leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2022 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Mar 2022 — Apr 2022 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting
▶ Show 6 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Jun 2019 — Feb 2020 [monthly]
Active Not Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2018 [monthly]
Recruiting NA
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Scientific Affairs, LLC
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .